DOI 10.1016/j.jhepr.2026.102002
Atezolizumab-bevacizumab with or without cisplatin-based HAIC for unresectable HCC: A randomized phase II trial.
Аннотация
BACKGROUND & AIMS: Atezolizumab plus bevacizumab (ATZ/BEV) is the global standard first-line treatment for unresectable hepatocellular carcinoma (HCC). However, the objective response rate (ORR) is approximately 30%. Hepatic arterial infusion chemotherapy (HAIC) with cisplatin may enhance its efficacy through locoregional cytoreduction and immunological modulation. We conducted a randomized phase II trial to evaluate whether sequential cisplatin HAIC plus ATZ/BEV (CDDP+ATZ/BEV) improves clinical outcomes compared to ATZ/BEV alone.
METHODS
In this multicenter, open-label trial, patients with unresectable HCC were randomized 1:1 to receive cisplatin HAIC within 8 weeks before initiation of ATZ/BEV or ATZ/BEV alone. The primary endpoint was ORR.
RESULTS
Between December 2021 and December 2024, 70 patients were enrolled in this study (CDDP+ATZ/BEV, n = 35; ATZ/BEV, n = 35). The primary endpoint, ORR, was numerically higher in the CDDP+ATZ/BEV group than in the ATZ/BEV group but did not reach statistical significance (45.7% vs. 28.6%; p = 0.095). Median progression-free survival (PFS) was longer in the CDDP+ATZ/BEV group (8.3 vs. 6.6 months; HR 0.53; p = 0.036), and median duration of response was not reached vs. 4.6 months (HR 0.4; p = 0.11). The median overall survival (OS) was 28.1 vs. 31.0 months (HR 0.95; p = 0.88). Grade 3-4 treatment-related adverse events occurred in 20.0% and 22.9% of patients, respectively.
CONCLUSIONS
The primary endpoint of ORR was not met. However, exploratory analyses demonstrated longer PFS without additional safety concerns. Further evaluation in phase III trials is warranted.
IMPACT AND IMPLICATIONS: This multicenter randomized phase II trial provides evidence that sequential cisplatin hepatic arterial infusion chemotherapy followed by atezolizumab-bevacizumab may prolong disease control without increasing toxicity in patients with unresectable hepatocellular carcinoma. Although the primary endpoint was not met and the progression-free survival benefit was observed in exploratory analyses, these findings support further investigation of this strategy in phase III trials and provide a rationale for evaluating liver-directed combination approaches to optimize first-line immunotherapy.
CLINICAL TRIAL NUMBER: Japan Registry of Clinical Trials (jRCTs061210065).
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.